Clinicians may safely use ranibizumab 0.5 mg in patients with bilateral age-related macular degeneration (AMD) as well as those with best-corrected visual acuity (BCVA) of less than 2/10, an Italian real-life study suggests.
This article was reviewed by Rahul N. Khurana, MD
This article was reviewed by David S. Boyer, MD
Special to Ophthalmology Times®
This article was reviewed by Jeffrey S. Heier, MD
Age-related macular degeneration (AMD) is the leading cause of blindness worldwide.
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process